enkephalin--leucine-2-alanine and naltrindole

enkephalin--leucine-2-alanine has been researched along with naltrindole* in 44 studies

Other Studies

44 other study(ies) available for enkephalin--leucine-2-alanine and naltrindole

ArticleYear
[DADLE suppresses the proliferation of human liver cancer HepG2 cells by activation of PKC pathway and elevates the sensitivity to cis-diammine dichloridoplatium].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:6

    To investigate the effect of DADLE, a δ-opioid receptor agonist, on the proliferation of human liver cancer HepG2 cells and explore the mechanism involving PKC pathway.. HepG2 cells were treated with DADLE at different doses (0.01, 0.1, 1.0 and 10 µmol/L). Cell viability was determined using methyl thiazolyl terazolium (MTT) assay. The expression of PKC mRNA and p-PKC protein were examined by RT-PCR and Western blot assay. After treated separately with DADLE plusing NAL or PMA, the cell cycle of HepG2 cells was analyzed by flow cytometer. MTT was used to detect their proliferation capacity and Western blot was used to examine the p-PKC expression. The growth inhibitory rate of HepG2 cells treated with DADLE and cis-diammine dichloridoplatinum (CDDP) was analyzed.. DADLE at different concentrations showed an inhibitory effect on the proliferation of HepG2 cells though inhibiting the expression of PKC mRNA and p-PKC protein. The results of flow cytometry showed that compared with the control group, the percentage of S + G(2)/M cells in DADLE-treated group was lowered by 3.94% (P < 0.01). Meanwhile, after treated with NAL and PMA, the percentage was elevated by 3.22% and 3.63%, respectively (P < 0.01). The MTT and Western blot assays showed that compared with the control group, the values of A570 and p-PKC protein levels in the HepG2 cells of DADLE-treated group were significantly decreased (P < 0.01). After treatment with NAL and PMA, the values of A570 and p-PKC protein levels were elevated significantly (P < 0.01). The growth inhibitory rate of DADLE + CDDP group was 79.9%, significantly lower than 25.2% and 43.2% of the DADLE and CDDP groups, respectively.. Activation of δ-opioid receptor by DADLE inhibits the apoptosis of human liver cancer HepG2 cells. The underlying mechanism may be correlated with PKC pathway. DADLE can enhance the chemosensitivity of HepG2 cells to CDDP.

    Topics: Antineoplastic Agents; Cell Cycle; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enkephalin, Leucine-2-Alanine; Hep G2 Cells; Humans; Naltrexone; Phosphorylation; Protein Kinase C; Receptors, Opioid, delta; RNA, Messenger; Signal Transduction; Tetradecanoylphorbol Acetate

2012
Activation of the δ-opioid receptor inhibits serum deprivation-induced apoptosis of human liver cells via the activation of PKC and the mitochondrial pathway.
    International journal of molecular medicine, 2011, Volume: 28, Issue:6

    Apoptosis of human liver cells is commonly found in liver diseases and liver surgery and directly affects their prognosis. Recent studies have found that δ-opioid receptors, abundant in the membranes of hepatic cells, participate in the oncogenesis and progression of liver tumors, viral hepatitis, liver cirrhosis and other diseases. The purpose of this study was to analyze the effect of the activation of the δ-opioid receptor on liver cell apoptosis and explore its relationship with PKC and the mitochondrial pathway. Hepatic cells were serum-deprived to induce apoptosis in vitro. During the period of apoptosis, mitochondrial membrane potential decreased, protein levels of cytosolic cytochrome c increased and the expression of Bcl-2 decreased, indicating that apoptosis was specifically induced by the mitochondrial pathway. Importantly, activation of δ-opioid receptors reversed the apoptotic state of hepatic cells. Following δ-opioid receptor activation, the mitochondrial membrane potential remained stable, and the expression of cytosolic cytochrome c and Bax decreased. These data suggest that δ-opioid receptor activation specifically inhibits the mitochondrial apoptotic pathway. In addition, activation of the δ-opioid receptor apparently increased the levels of PKC; blocking the PKC pathway led to increased apoptosis of liver cells, which was not affected by the activation of δ-opioid receptor. Blocking the PKC pathway led to increased apoptosis of liver cells, which was associated with δ-opioid receptor activation. Therefore, the PKC pathway is involved in the anti-apoptotic effects of the δ-opioid receptor on liver cells.

    Topics: Apoptosis; bcl-2-Associated X Protein; Cytochromes c; Enkephalin, Leucine-2-Alanine; Gene Expression; Hepatocytes; Humans; Liver; Liver Diseases; Membrane Potential, Mitochondrial; Mitochondria; Naltrexone; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Receptors, Opioid, delta; Serum; Signal Transduction; Stress, Physiological; Tumor Cells, Cultured

2011
A GPCR/secretase complex regulates beta- and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis.
    Cell research, 2010, Volume: 20, Issue:2

    Dysregulation of beta-site APP-cleaving enzyme (BACE) and/or gamma-secretase leads to anomalous production of amyloid-beta peptide (Abeta) and contributes to the etiology of Alzheimer's disease (AD). Since these secretases mediate proteolytic processing of numerous proteins, little success has been achieved to treat AD by secretase inhibitors because of inevitable undesired side effects. Thus, it is of importance to unravel the regulatory mechanisms of these secretases. Here, we show that delta-opioid receptor (DOR) promotes the processing of Abeta precursor protein (APP) by BACE1 and gamma-secretase, but not that of Notch, N-cadherin or APLP. Further investigation reveals that DOR forms a complex with BACE1 and gamma-secretase, and activation of DOR mediates the co-endocytic sorting of the secretases/receptor complex for APP endoproteolysis. Dysfunction of the receptor retards the endocytosis of BACE1 and gamma-secretase and thus the production of Abeta. Consistently, knockdown or antagonization of DOR reduces secretase activities and ameliorates Abeta pathology and Abeta-dependent behavioral deficits, but does not affect the processing of Notch, N-cadherin or APLP in AD model mice. Our study not only uncovers a molecular mechanism for the formation of a DOR/secretase complex that regulates the specificity of secretase for Abeta production but also suggests that intervention of either formation or trafficking of the GPCR/secretase complex could lead to a new strategy against AD, potentially with fewer side effects.

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Carbamates; Cells, Cultured; Dipeptides; Enkephalin, Leucine-2-Alanine; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Multiprotein Complexes; Naltrexone; Narcotic Antagonists; Protein Transport; Receptors, G-Protein-Coupled; Receptors, Opioid, delta; Substrate Specificity; Transport Vesicles

2010
Effects of intracerebroventricular application of the delta opioid receptor agonist [D-Ala2, D-Leu5] enkephalin on neurological recovery following asphyxial cardiac arrest in rats.
    Neuroscience, 2010, Jun-30, Volume: 168, Issue:2

    The delta opioid receptor (DOR) agonist [D-Ala2, D-Leu5] enkephalin (DADLE) has been implicated as a novel neuroprotective agent in the CNS. The current study was designed to evaluate the effects of intracerebroventricular (ICV) application of DADLE on neurological outcomes following asphyxial cardiac arrest (CA) in rats. Male Sprague-Dawley rats were randomly assigned to four groups: Sham group, CA group, DADLE group (DADLE+CA), and Naltrindole group (Naltrindole and DADLE+CA). All drugs were administered into the left cerebroventricle 30 min before CA. CA was induced by 8-min asphyxiation and the animals were resuscitated with a standardized method. DOR protein expression in the hippocampus was significantly increased in the CA group at 1 h after restoration of spontaneous circulation (ROSC) compared with the Sham group. As time progressed, expression of DOR proteins decreased gradually in the CA group. Treatment with DADLE alone or co-administration with Naltrindole reversed the down-regulation of DOR proteins in the hippocampus induced by CA at 24 h after ROSC. Compared with the CA group, the DADLE group had persistently better neurological functional recovery, as assessed by neurological deficit score (NDS) and Morris water maze trials. The number of surviving hippocampal CA1 neurons in the DADLE group was significantly higher than those in the CA group. However, administration of Naltrindole abolished most of the neuroprotective effects of DADLE. We conclude that ICV administration of DADLE 30 min before asphyxial CA has significant protective effects in attenuating hippocampal CA1 neuronal damage and neurological impairments, and that DADLE executes its effects mainly through DOR.

    Topics: Animals; Asphyxia; CA1 Region, Hippocampal; Cell Survival; Enkephalin, Leucine-2-Alanine; Heart Arrest; Injections, Intraventricular; Male; Maze Learning; Naltrexone; Neurons; Neuroprotective Agents; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta

2010
Neuroprotective role of delta-opioid receptors against mitochondrial respiratory chain injury.
    Brain research, 2009, Feb-03, Volume: 1252

    It is recognized in recent years that activation of delta-opioid receptor (DOR) elicits neuroprotection against hypoxia and ischemia. However, the underlying mechanisms are not well understood yet. Mitochondrial dysfunction plays a key role in hypoxic neuronal injury, but the effect of DOR activation on neurons with a mitochondrial respiratory chain deficiency is poorly elucidated. In this study we tested the effects of DOR activation and inhibition on cultured cortical neurons after inhibiting mitochondrial respiratory chain with sodium azide (NaN(3)) in days 8 cultures. Neuronal injury was assessed by lactate dehydrogenase release. Changes in DOR proteins were investigated using an antibody against the N-terminus of the DOR, which recognizes the 60, 48, and 32 kDa proteins. Our main findings are that 1) delta- but not mu-opioid receptor activation reduces NaN(3)-induced neuronal damage, and this neuroprotective effect is abolished by DOR antagonist (naltrindole, NTI); 2) prolonged DOR inhibition with NTI further increases NaN(3)-induced neuronal damage; 3) NaN(3) treatment down-regulates DOR protein levels in neurons, and the 60 and 32 kDa proteins are particularly sensitive; 4) DADLE, besides activating DOR directly, also reverses the decrease of neuronal DOR protein levels induced by NaN(3), which may contribute greatly to its neuroprotective effect; 5) NTI reverses NaN(3)-induced down-regulation of DOR proteins as well, the effect of NTI amplifying NaN(3)-induced neuronal damage therefore is probably due to its inhibition on DOR activity only. In conclusion, these data suggest that DOR activation plays an important role in neuroprotection against mitochondrial respiratory chain injury.

    Topics: Animals; Blotting, Western; Cells, Cultured; Cerebral Cortex; Electron Transport; Electrophoresis, Polyacrylamide Gel; Enkephalin, Leucine-2-Alanine; Immunoprecipitation; L-Lactate Dehydrogenase; Mitochondria; Naltrexone; Narcotic Antagonists; Neurons; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, mu; Sodium Azide

2009
Delta opioid agonist [D-Ala2, D-Leu5] enkephalin (DADLE) reduced oxygen-glucose deprivation caused neuronal injury through the MAPK pathway.
    Brain research, 2009, Oct-06, Volume: 1292

    It has been demonstrated that [D-Ala2, D-Leu5] enkephalin (DADLE), a delta opioid agonist, protected neuron from hypoxic neuronal injury by activating the delta opioid receptor (DOR). However, whether DADLE can prevent neuronal injury induced by severe hypoxia like oxygen-glucose deprivation (OGD) is not clear. Here, we investigated whether DADLE has a protective effect against neuronal injury induced by oxygen-glucose deprivation. Neuron viability was measured by MTT and neuron injury was assessed by lactate dehydrogenase (LDH) release. Protein expression was examined by Western blot. The results showed that DADLE protected the cortical neuron in a dose-dependent way from OGD injury. And this neuroprotective effect could be completely blocked by delta 2 opioid antagonist Naltrindole. DADLE increased phosphorylation of ERK and prevented OGD-induced p38 phosphorylation. Neither DADLE nor Naltrindole had any appreciable effect on phosphorylation of JNK. One of the protective mechanisms of DADLE on OGD neurons may be due to the dynamic balance between the activation of ERK and the p38.

    Topics: Animals; Brain Injuries; Cell Hypoxia; Cell Survival; Cells, Cultured; Cerebral Cortex; Dose-Response Relationship, Drug; Enkephalin, Leucine-2-Alanine; Extracellular Signal-Regulated MAP Kinases; Glucose; JNK Mitogen-Activated Protein Kinases; L-Lactate Dehydrogenase; MAP Kinase Signaling System; Naltrexone; Narcotic Antagonists; Neurons; Neuroprotective Agents; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta

2009
delta-Opioid receptor stimulation enhances the growth of neonatal rat ventricular myocytes via the extracellular signal-regulated kinase pathway.
    Clinical and experimental pharmacology & physiology, 2008, Volume: 35, Issue:1

    1. The aims of the present study were to determine whether delta-opioid receptor stimulation enhanced proliferation of and to investigate the role of the extracellular signal-regulated kinase (ERK) pathway in ventricular myocytes from neonatal rats. 2. At concentratins ranging from 10 nmol/L to 10 micromol/L, [D-Ala2,D-Leu5]enkephalin (DADLE) concentration-dependently promoted myocardial growth and DNA synthesis and altered the cytoskeleton. 3. At 1 micromol/L, DADLE also increased the expression and phosphorylation of ERK. 4. These effects of 1 micromol/L DADLE were abolished by 10 micromol/L naltrindole, a selective delta-opioid receptor antagonist, 10 nmol/L U0126, a selective ERK antagonist, 1 micromol/L staurosporine, an inhibitor of protein kinase (PK) C, and 100 micromol/L Rp-adenosine 3',5'-cyclic monophosphorothioate triethylammonium salt hydrate (Rp-cAMPS), an inhibitor of PKA. 5. In conclusion, delta-opioid receptor stimulation enhances the proliferation and development of the ventricular myocytes of neonatal rats. The ERK pathway and related signalling mechanisms, namely PKC and PKA, are involved.

    Topics: Analgesics, Opioid; Animals; Animals, Newborn; Butadienes; Cell Proliferation; Cells, Cultured; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cytoskeleton; Dose-Response Relationship, Drug; Enkephalin, Leucine-2-Alanine; Extracellular Signal-Regulated MAP Kinases; Heart Ventricles; Myocytes, Cardiac; Naltrexone; Narcotic Antagonists; Nitriles; Phosphorylation; Protein Kinase C; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Signal Transduction; Staurosporine; Thionucleotides; Time Factors

2008
Mu-opioid receptor in the nucleus submedius: involvement in opioid-induced inhibition of mirror-image allodynia in a rat model of neuropathic pain.
    Neurochemical research, 2008, Volume: 33, Issue:10

    The current study investigated the roles of various subtypes of opioid receptors expressed in the thalamic nucleus submedius (Sm) in inhibition of mirror-image allodynia induced by L5/L6 spinal nerve ligation in rats. Morphine was microinjected into the Sm, which produced a dose-dependent inhibition of mirror-image allodynia; this effect was antagonized by pretreatment with non-selective opioid receptor antagonist naloxone. Microinjections of endomorphin-1 (mu-receptor agonist), or [D-Ala(2), D-Leu(5)]-enkephalin (DADLE, delta-/mu-receptor agonist), also inhibited mirror-image allodynia, and these effects were blocked by the selective mu-receptor antagonist, beta-funaltrexamine hydrochloride. The DADLE-induced inhibition, however, was not influenced by the delta-receptor antagonist naltrindole. The kappa-receptor agonist, spiradoline mesylate salt, failed to alter the mirror-image allodynia. These results suggest that Sm opioid receptor signaling is involved in inhibition of mirror-image allodynia; this effect is mediated by mu- (but not delta- and kappa-) opioid receptors in the rat model of neuropathic pain.

    Topics: Animals; Behavior, Animal; Disease Models, Animal; Enkephalin, Leucine-2-Alanine; Hyperalgesia; Ligation; Male; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Neuralgia; Oligopeptides; Pain Measurement; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Spinal Nerves; Thalamic Nuclei

2008
Dose-dependent neuroprotection of delta opioid peptide [D-Ala2, D-Leu5] enkephalin in neuronal death and retarded behavior induced by forebrain ischemia in rats.
    Neuroscience letters, 2007, Aug-16, Volume: 423, Issue:2

    Cerebral ischemic insult, mainly induced by cardiovascular disease, is one of the most severe neurological diseases in clinical. There's mounting evidence showing that delta opioid agonist [D-Ala2, D-Leu5] enkephalin (DADLE) has a tissue-protective effect. However, whether this property is effective to prevent neuronal death induced by forebrain ischemia is not clear. This study was aimed to investigate whether intracerebroventricular (ICV) administration of DADLE has a neuroprotective effect against forebrain ischemia in rats. We found in our study that administration of DADLE 45 min before forebrain ischemia had significant protective effect against CA1 neuronal lose. Further more, we found that DADLE had a dose-dependent protection for improving behavioral retardation revealed by Morris water maze and motor score test, while naltrindole, the antagonist of delta opioid receptor, partially abolished neuroprotective effect of DADLE, which implicated that both opioid and non-opioid systems are involved in ischemic insults and neuroprotection.

    Topics: Animals; Behavior, Animal; Brain Ischemia; Cell Death; Dose-Response Relationship, Drug; Enkephalin, Leucine-2-Alanine; Injections, Intraventricular; Male; Naltrexone; Narcotic Antagonists; Neurons; Neuroprotective Agents; Prosencephalon; Rats; Rats, Sprague-Dawley

2007
Effects of delta-opioid receptor stimulation and inhibition on hippocampal survival in a rat model of forebrain ischaemia.
    British journal of anaesthesia, 2007, Volume: 99, Issue:4

    It has been reported that delta-opioid (DOP) receptor agonists may be neuroprotective in the central nervous system. However, the DOP agonist [d-Ala(2), d-Leu(5)]enkephalin (DADLE) does not produce neuroprotection in severe forebrain ischaemia. The aim of this study was to examine the effects of DADLE on hippocampal neurone survival against less severe forebrain ischaemia.. Intraperitoneal injection of DADLE (0 or 16 mg kg(-1)) in male Sprague-Dawley rats was performed 30 min before ischaemia. Severe (10 min), moderate (8 min), or mild (6 min) forebrain ischaemia was produced by bilateral carotid occlusion combined with hypotension (35 mm Hg) under isoflurane (1.5%) anaesthesia. Naltrindole (10 mg kg(-1)) (DOP antagonist) was administered 30 min before DADLE in order to confirm DOP receptor activation in the neuroprotective efficacy of DADLE. Naltrindole alone was also administered 30 min before ischaemia to examine endogenous DOP agonism as a self-protecting mechanism against ischaemia. All animals were evaluated neurologically and histologically after a 1 week recovery period.. DADLE improved neurone survival in hippocampal CA3 and dentate gyrus (DG) sectors. CA1 neurones were not protected against moderate and mild ischaemia. Naltrindole abolished DADLE neuroprotection in the CA3 and DG after both moderate and mild ischaemia. Interestingly, regardless of co-administration of DADLE, naltrindole significantly worsened neuronal injury in the CA1 region after mild ischaemia.. These results suggest that DADLE provides limited neuroprotection to relatively ischaemia-resistant regions but not to selectively vulnerable regions. This was probably mediated by DOP stimulation. Pre-ischaemic treatment with a DOP antagonist, regardless of co-administration of DADLE, worsened neuronal damage at the selectively vulnerable regions only after mild forebrain ischaemia. These data suggest that DOP activation with endogenous DOP ligand may be involved in self-protecting ischaemia-sensitive regions of the brain.

    Topics: Animals; Brain Ischemia; Cell Survival; Drug Evaluation, Preclinical; Enkephalin, Leucine-2-Alanine; Hippocampus; Male; Naltrexone; Narcotic Antagonists; Neurons; Neuroprotective Agents; Prosencephalon; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta

2007
Rapid hypoxia preconditioning protects cortical neurons from glutamate toxicity through delta-opioid receptor.
    Stroke, 2006, Volume: 37, Issue:4

    Hypoxia preconditioning (HPC), rapid or delayed, has been reported to induce neuroprotection against subsequent severe stress. Because delta-opioid receptor (DOR) plays an important role in delayed HPC-induced neuroprotection against severe hypoxic injury, we asked whether DOR is also involved in the rapid HPC-induced neuroprotection.. Cultured rat cortical neurons at culture days 8 to 9 were exposed to a short-term hypoxia (1% O2 for 30 minutes) to induce HPC followed by 30-minute normoxia before exposing to glutamate toxicity (100 micromol/L; 4 hours). Neuronal viability was assessed by lactate dehydrogenase leakage and morphological assessment. Protein and mRNA levels of DOR were detected by receptor binding and RT-PCR, respectively. Naltrindole was used to block DOR. Developmental changes in NMDA receptor expression was measured by Western blots.. HPC significantly reduced the glutamate-induced neuronal injury. Receptor binding showed that HPC increased DADLE (a DOR ligand) binding density in the cultured cortical neurons by >90% over control level (P<0.05), although RT-PCR did not detect any appreciable change in DOR mRNA. DOR inhibition with naltrindole had no effect on neuronal injury and completely abolished the HPC-induced neuroprotection. In contrast to HPC-induced increase in DADLE binding density, prolonged hypoxia caused severe neuronal injury with a significant decrease in DADLE binding density and DOR mRNA level.. DOR is involved in neuroprotection induced by rapid HPC in cortical neurons.

    Topics: Animals; Cells, Cultured; Cellular Senescence; Cerebral Cortex; Enkephalin, Leucine-2-Alanine; Glutamic Acid; Hypoxia; Ischemic Preconditioning; L-Lactate Dehydrogenase; N-Methylaspartate; Naltrexone; Narcotic Antagonists; Neurons; Rats; Receptors, Opioid, delta; RNA, Messenger; Time Factors; Up-Regulation

2006
Characterisation of opioid receptors involved in modulating circular and longitudinal muscle contraction in the rat ileum.
    British journal of pharmacology, 2005, Volume: 144, Issue:5

    1. The aim of the present investigation was to characterise the opioid receptor subtypes present in the rat ileum using a method that detects drug action on the enteric nerves innervating the circular and longitudinal muscles. 2. Neurogenic contractions were reversibly inhibited by morphine (circular muscle pEC50, 6.43+/-0.17, Emax 81.7+/-5.0%; longitudinal muscle pEC50, 6.65+/-0.27, Emax 59.7+/-7.8%), the mu-opioid receptor-selective agonist, DAMGO ([D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin acetate) (circular pEC50, 7.85+/-0.04, Emax 97.8+/-3.6%; longitudinal pEC50, 7.35+/-0.09, Emax 56.0+/-6.1%), the delta-selective agonist DADLE ([D-Ala2,D-Leu5]enkephalin acetate) (circular pEC50, 7.41+/-0.17, Emax, 93.3+/-8.4%; longitudinal pEC50, 6.31+/-0.07, Emax 66.5+/-5.2%) and the kappa-selective agonist U 50488H (trans-(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide methanesulphonate) (circular pEC50, 5.91+/-0.41, Emax, 83.5+/-26.8%; longitudinal pEC50, 5.60+/-0.08, Emax 74.3+/-7.2%). Agonist potencies were generally within expected ranges for activity at the subtype for which they are selective, except for U 50488H, which was less potent than expected. 3. The mu and delta receptor-selective antagonists, CTAP (H-D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) and naltrindole, caused progressive, parallel rightward shifts in the DAMGO and DADLE curves, respectively. Analysis indicated conformity to theoretical simple competitive antagonist behaviour. U 50488H effects were insensitive to the kappa-selective antagonist, n-BNI. A high concentration (1 microM) of naltrexone caused apparent potentiation of U 50488H effects. 4. CTAP pK(B) estimates were consistent with previously reported values for mu receptor antagonism (circular 7.84+/-0.17, longitudinal 7.64+/-0.35). However, the naltrindole pK(B) estimates indicated lower antagonist potency than expected (circular 8.22+/-0.23, longitudinal 8.53+/-0.35). 5. It is concluded that mu and possibly atypical delta receptors (but not kappa receptors) mediate inhibition of contraction in this model. Nonopioid actions of U 50488H are probably responsible for the inhibitory effects seen with this compound.

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Electric Stimulation; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, Leucine-2-Alanine; Enteric Nervous System; Female; Guinea Pigs; Ileum; In Vitro Techniques; Male; Morphine; Muscle Contraction; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid, delta; Receptors, Opioid, mu

2005
Delta-opioid receptor antagonists exhibit properties of partial delta-receptor agonists in isolated perfused heart.
    Bulletin of experimental biology and medicine, 2004, Volume: 138, Issue:4

    Perfusion of the isolated intact rat heart with Krebs-Henseleit solution containing agonists ((-)-TAN-67, DPDPE, and dalargin) or antagonists of delta-opioid receptors (naltrindole, TIPP[psi], and ICI 174,864) in a final concentration of 0.1 mg/liter was followed by a decrease in the heart rate, end-diastolic pressure, contraction rate, relaxation rate, and left ventricular developed pressure. Perfusion with a solution containing the delta-opioid receptor agonist DPDPE or delta-antagonists naltrindole, TIPP[psi], and ICI 174,864 before modeling of global ischemia increased the severity of reperfusion-induced contractile dysfunction in the myocardium. Our results suggest that delta-opioid receptor antagonists in vitro exhibit properties of partial delta-receptor agonists.

    Topics: Animals; Enkephalin, D-Penicillamine (2,5)-; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Heart; In Vitro Techniques; Male; Myocardial Contraction; Myocardial Ischemia; Naltrexone; Oligopeptides; Perfusion; Quinolines; Rats; Rats, Wistar; Receptors, Opioid, delta

2004
Phosphorylation of activating transcription factor in murine splenocytes through delta opioid receptors.
    Cellular immunology, 2003, Volume: 221, Issue:2

    Delta opioid receptors (DORs) modulate TCR signaling through the mitogen-activated protein kinases (MAPKs), ERKs 1 and 2. These studies determined whether a DOR agonist alone ([D-Ala(2)-D-Leu(5)]enkephalin; DADLE) affects phosphorylation of the activating transcription factor (ATF-2) and its interaction with the MAPK, c-Jun NH(2)-terminal kinase (JNK). DOR expression was induced on murine splenocytes by anti-CD3 and then quiescent cells were treated with DADLE. DADLE, itself, dose-dependently induced maximal phosphorylation of ATF-2 within 5-10min; naltrindole, a specific antagonist, abolished this. Anti-ATF-2 immunoprecipitates from control and DADLE-treated splenocytes showed a dominant 59kDa phosphorylated band and a 71kDa band. DADLE stimulated phosphorylation of both bands, although the 71kDa band was selectively immunoprecipitated by anti-JNK. Thus, DADLE stimulated phosphorylation of 71kDa ATF-2 and its association with JNK, suggesting that JNK is activated through DORs. Along with previous observations, these studies suggest that lymphocyte DORs can affect the activation of MAPKs by TCR-independent stimulation (e.g., JNK) or indirectly by modulating TCR-dependent stimulation (e.g., ERK).

    Topics: Activating Transcription Factor 2; Animals; Blotting, Western; Cyclic AMP Response Element-Binding Protein; Enkephalin, Leucine-2-Alanine; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Naltrexone; Narcotic Antagonists; Phosphorylation; Receptors, Opioid, delta; Signal Transduction; Specific Pathogen-Free Organisms; Spleen; Transcription Factors

2003
HL-1 myocytes exhibit PKC and K(ATP) channel-dependent delta opioid preconditioning.
    The Journal of surgical research, 2003, Volume: 114, Issue:2

    Opioid preconditioning protects the myocardium against ischemia/reperfusion (IR) injury. By enhancing cardiomyocyte viability, opioids can enhance cardiac function and recovery from IR injury during acute cardiac care. The myocyte model HL-1 is an immortalized, mouse atrial cell line that expresses functional delta-opioid receptors. The HL-1 myocyte may be useful for IR injury research exploring opioid cardioprotection.. In study I, microplates of HL-1 were subjected to 10 min pre-treatment with either basal media, delta-opioid agonist DADLE(10uM), or DADLE(10uM) + delta-antagonist naltrindole (10uM). Study II treatment groups included PKC inhibitor chelerythrine (2uM), K(ATP) channel closer glybenclamide (100uM), or mitochondrial K(ATP) channel opener diazoxide (100uM) administered in various combinations followed by DADLE (10uM) or control. Microplates were subjected to normal oxygen/substrate conditions or ischemic (<1% 0(2)) and substrate deficient (10 uM 2-Deoxyglucose versus 10 mM glucose) conditions, then reperfused with normal oxygen and glucose-containing media. Microplate supernatants were subjected to lactate dehydrogenase (LDH) assay.. Compared to untreated control, the LDH assay showed significant reduction in opioid-only pretreated groups at all time points. These effects were attenuated with delta-opioid antagonist co-administration. Co-administration of non-selective K(ATP) channel closer glybenclamide and DADLE abolished DADLE cytoprotection, while selective mitochondrial K(ATP) opener diazoxide mimicked DADLE cytoprotection Co-administration of chelerythrine and DADLE significantly reduced chelerythrine cytotoxicity.. Delta-opioid preconditioning of HL-1 myocytes significantly decreased necrosis from in vitro simulated ischemia/reperfusion as measured by LDH release; this effect was reversed by delta-antagonist naltrindole. Cytoprotection was PKC and K(ATP) channel-dependent. HL-1 myocytes exhibit opioid-induced cytoprotection from IR injury, and present a novel model of pharmacologic preconditioning.

    Topics: Alkaloids; Animals; Benzophenanthridines; Cell Line; Enkephalin, Leucine-2-Alanine; Enzyme Inhibitors; Heart; Ischemic Preconditioning, Myocardial; Kinetics; Membrane Proteins; Muscle Cells; Myocardial Reperfusion; Myocardium; Naltrexone; Phenanthridines; Potassium Channels; Protein Kinase C; Receptors, Opioid, delta

2003
Neuroprotective role of delta-opioid receptors in cortical neurons.
    American journal of physiology. Cell physiology, 2002, Volume: 282, Issue:6

    We recently demonstrated that delta-opioid receptor (DOR) activation protects cortical neurons against glutamate-induced injury. Because glutamate is a mediator of hypoxic injury in neurons, we hypothesized that DOR is involved in neuroprotection during O2 deprivation and that its activation/inhibition may alter neuronal susceptibility to hypoxic stress. In this work, we tested the effect of opioid receptor activation and inhibition on cultured cortical neurons in hypoxia (1% O2). Cell injury was assessed by lactate dehydrogenase release, morphology-based quantification, and live/dead staining. Our results show that 1) immature neurons (days 4 and 6) were not significantly injured by hypoxia until 72 h of exposure, whereas day 8 neurons were injured after only 24-h hypoxia; 2) DOR inhibition (naltrindole) caused neuronal injury in both day 4 and day 8 normoxic cultures and further augmented hypoxic injury in these neurons; 3) DOR activation ([D-Ala2,D-Leu5]enkephalin) reduced neuronal injury in day 8 cultures after 24 h of normoxic or hypoxic exposure and attenuated naltrindole-induced injury with prolonged exposure; and 4) mu- or kappa-opioid receptor inhibition (beta-funaltrexamine or nor-binaltorphimine) had little effect on neurons in either normoxic or hypoxic conditions. Collectively, these data suggest that DOR plays a crucial role in neuroprotection in normoxic and hypoxic environments.

    Topics: Animals; Cell Count; Cell Differentiation; Cell Hypoxia; Cell Survival; Cells, Cultured; Cerebral Cortex; Enkephalin, Leucine-2-Alanine; Hypoxia, Brain; L-Lactate Dehydrogenase; Naltrexone; Narcotic Antagonists; Neurons; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, kappa; Time Factors

2002
The human delta opioid receptor activates G(i1)alpha more efficiently than G(o1)alpha.
    Journal of neurochemistry, 2001, Volume: 76, Issue:6

    To assess the relative capacity of the human delta opioid receptor to activate closely related G proteins, fusion proteins were constructed in which the alpha-subunits of either G(i1) or G(o1), containing point mutations to render them insensitive to the actions of pertussis toxin, were linked in-frame with the C-terminus of the receptor. Following transient and stable expression in HEK 293 cells, both constructs bound the antagonist [(3)H]naltrindole with high affinity. D-ala(2),D-leu(5) Enkephalin effectively inhibited forskolin-stimulated adenylyl cyclase activity in intact cells in a concentration-dependent, but pertussis toxin-insensitive, manner. The high-affinity GTPase activity of both constructs was also stimulated by D-ala(2),D-leu(5) enkephalin with similar potency. However, enzyme kinetic analysis of agonist stimulation of GTPase activity demonstrated that the GTP turnover number produced in response to D-ala(2),D-leu(5) enkephalin was more than three times greater for G(i1)alpha than for G(o1)alpha. As the effect of agonist in both cases was to increase V:(max) without increasing the observed K:(m) for GTP, this is consistent with receptor promoting greater guanine nucleotide exchange, and thus activation, of G(i1)alpha compared with G(o1)alpha. An equivalent fusion protein between the human mu opioid receptor-1 and G(i1)alpha produced a similar D-ala(2),D-leu(5) enkephalin-induced GTP turnover number as the delta opioid receptor-G(i1)alpha fusion construct, consistent with agonist occupation of these two opioid receptor subtypes being equally efficiently coupled to activation of G(i1)alpha.

    Topics: Adenylyl Cyclases; Cell Line; Colforsin; Diprenorphine; Enkephalin, Leucine-2-Alanine; GTP Phosphohydrolases; GTP-Binding Protein alpha Subunits, Gi-Go; Guanosine Triphosphate; Heterotrimeric GTP-Binding Proteins; Humans; Kinetics; Naltrexone; Polymerase Chain Reaction; Receptors, Opioid, delta; Recombinant Fusion Proteins; Recombinant Proteins; Transfection

2001
Control of the efficiency of agonist-induced information transfer and stability of the ternary complex containing the delta opioid receptor and the alpha subunit of G(i1) by mutation of a receptor/G protein contact interface.
    Neuropharmacology, 2001, Volume: 41, Issue:3

    Fusion proteins were constructed between the delta opioid receptor and forms of the alpha subunit of G(i1) in which cysteine(351) was mutated to a range of amino acids. GDP reduced the binding of the agonist [(3)H]DADLE but not the antagonist [(3)H]naltrindole to both the receptor alone and all the delta opioid receptor-Cys(351)XaaG(i1)alpha fusion proteins. For the fusion proteins the pEC(50) for GDP was strongly correlated with the n-octanol/H(2)O partition co-efficient of G protein residue(351). Fusion proteins in which this residue was either isoleucine or glycine had similar observed binding kinetics for [(3)H]DADLE. However, the rate of dissociation of [(3)H]DADLE was substantially greater for the glycine-containing fusion protein than that containing isoleucine, indicating that more hydrophobic residues imbued greater stability to the agonist-receptor-G protein ternary complex. This resulted in a higher affinity of binding of [(3)H]DADLE to the fusion protein containing isoleucine(351). In expectation with the binding data, maximal DADLE-stimulated GTP hydrolysis by the isoleucine(351)-containing fusion protein was two-fold greater and the potency of DADLE seven-fold higher than for the version containing glycine. These results demonstrate that the stability of the ternary complex between delta opioid receptor, G(i1)alpha and an agonist (but not antagonist) ligand is dependent upon the nature of residue(351) of the G protein and that this determines the effectiveness of information flow from the receptor to the G protein.

    Topics: Cell Membrane; Cells, Cultured; Enkephalin, Leucine-2-Alanine; GTP Phosphohydrolases; GTP-Binding Proteins; Heterotrimeric GTP-Binding Proteins; Humans; Kinetics; Naltrexone; Narcotic Antagonists; Oligonucleotides, Antisense; Receptors, sigma; Recombinant Fusion Proteins; Transfection

2001
Characterization of delta-opioid receptors and effect of enkephalins on IRD 98 rat epithelial intestinal cell line.
    Pflugers Archiv : European journal of physiology, 2000, Volume: 439, Issue:5

    Using 3H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (3H-DADLE) as a radioligand, delta-opioid binding sites on the IRD 98 rat epithelial cell line were identified. These sites were found to be reversible, saturable, specific and displayed high affinity for DADLE. Scatchard analysis revealed a dissociation constant (Kd) of 4.9+/-0.5 nmol/l, a maximum binding capacity (Bmax) of 1.7 pmol/mg protein, and 5x10(5) binding sites per cell. The presence of opioid receptors suggests the possibility that enkephalins directly control ion transport in enterocytes. In order to verify this hypothesis, investigations were designed to determine whether these receptors are functional and whether enkephalins can inhibit the stimulation of adenosine 3',5' cyclic monophosphate (cAMP) synthesis induced by cholera toxin. The increase in cAMP synthesis induced by cholera toxin was inhibited in a dose-dependent manner by H-Tyr-D-Ser-Gly-Phe-Leu-Thr-OH (DSLET), a delta-agonist. The enkephalinase inhibitor thiorphan potentiated this effect on IRD 98 cells, which contain enkephalinase. The action of DSLET was increased by 40% in the presence of this inhibitor. This effect was reversed by naltrindole, a potent delta-antagonist. Enkephalins can regulate intestinal secretion by acting directly on enterocytes: they thus have an antidiarrheal role, especially in the presence of an enkephalinase inhibitor.

    Topics: Analgesics, Opioid; Animals; Binding, Competitive; Cell Line; Cholera Toxin; Cyclic AMP; Dextrorphan; Enkephalin, Leucine-2-Alanine; Enkephalins; Epithelial Cells; Excitatory Amino Acid Antagonists; Fetus; Intestinal Secretions; Intestines; Kinetics; Levorphanol; Naltrexone; Narcotic Antagonists; Neprilysin; Protease Inhibitors; Rats; Receptors, Opioid, delta; Stereoisomerism; Thiorphan; Tritium

2000
Functional evidence that gastroprotection can be induced by activation of central alpha(2B)-adrenoceptor subtypes in the rat.
    European journal of pharmacology, 2000, May-19, Volume: 396, Issue:2-3

    Clonidine injected intracerebroventricularly (i.c.v.) (0.47 nmol/rat) exerted gastric mucosal protective effect against acidified ethanol. Evidence was obtained that the gastroprotective effect of clonidine was blocked by i.c.v. injected alpha(2)-adrenoceptor antagonists yohimbine (non-subtype selective antagonist), prazosin and 2-[2-(4-(O-methoxyphenyl)piperazin-1-yl)ethyl]-4,4-dimethyl-1,3-(2 H, 4H)-isoquinolindione (ARC-239) (representative alpha(2B/2C)-adrenoceptor blocking agents) and opioid receptor antagonists naloxone (a non-selective, moderately mu-opioid receptor preferring antagonist), naltrindole and naltriben delta-opioid receptor antagonists). The centrally injected naltrindole (0.5 nmol/rat) antagonised also the gastroprotective effect of clonidine --but not that of the delta-agonist [D-Ala(2), D-Leu(5)]enkephalin--administered peripherally. The results suggest that central alpha(2B/2C)-adrenoceptor subtypes and opioid--particularly delta--receptors are likely to be involved in the gastric mucosal protective effect of clonidine.

    Topics: Adrenergic alpha-Agonists; Animals; Brain; Clonidine; Enkephalin, Leucine-2-Alanine; Gastric Mucosa; Injections, Intraventricular; Male; Naloxone; Naltrexone; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-2

2000
Expression of functional delta opioid receptors in vascular smooth muscle.
    International journal of molecular medicine, 2000, Volume: 6, Issue:6

    We evaluated smooth muscle from human internal mammary artery and rat aorta for the presence of delta opioid receptors. Radioligand receptor competition studies using the delta-receptor selective agonist, [3H]-[D-Ala2, Met5] enkephalinamide (DAMA) suggested the expression of a high affinity binding site in rat and human blood vessels that was consistent with the delta-2 opioid receptor subtype. Using RT-PCR with primers to the cloned delta opioid receptor (DOR), a cDNA fragment identical to the known DOR sequence was obtained from the smooth muscle cell line, A-10. Stimulation of A-10 cells with DAMA resulted in a significant mobilization of intracellular calcium and membrane depolarization. Exposure of aortic rings denuded of endothelium to DAMA induced a naltrindole-senstive increase in contractile tone. These data demonstrate the presence of a functional DOR in vascular smooth muscle and a direct impact of opioids on vascular contractile tone.

    Topics: Animals; Aorta; Binding, Competitive; Calcium; Cell Line; Enkephalin, D-Penicillamine (2,5)-; Enkephalin, Leucine-2-Alanine; Enkephalin, Methionine; Gene Expression; Humans; In Vitro Techniques; Male; Membrane Potentials; Muscle, Smooth, Vascular; Naltrexone; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; RNA, Messenger; Vasoconstriction

2000
delta-, but not mu- and kappa-, opioid receptor activation protects neocortical neurons from glutamate-induced excitotoxic injury.
    Brain research, 2000, Dec-08, Volume: 885, Issue:2

    Recent observations from our laboratory have led us to hypothesize that delta-opioid receptors may play a role in neuronal protection against hypoxic/ischemic or glutamate excitotocity. To test our hypothesis in this work, we used two independent methods, i.e., "same field quantification" of morphologic criteria and a biochemical assay of lactate dehydrogenase (LDH) release (an index of cellular injury). We used neuronal cultures from rat neocortex and studied whether (1) glutamate induces neuronal injury as a function of age and (2) activation of opioid receptors (delta, mu and kappa subtypes) protects neurons from glutamate-induced injury. Our results show that glutamate induced neuronal injury and cell death and this was dependent on glutamate concentration, exposure period and days in culture. At 4 days, glutamate (up to 10 mM, 4 h-exposure) did not cause apparent injury. After 8-10 days in culture, neurons exposed to a much lower dose of glutamate (100 microM, 4 h) showed substantial neuronal injury as assessed by morphologic criteria (>65%, n=23, P<0.01) and LDH release (n=16, P<0. 001). Activation of delta-opioid receptors with 10 microM DADLE reduced glutamate-induced injury by almost half as assessed by the same criteria (morphologic criteria, n=21, P<0.01; LDH release, n=16, P<0.01). Naltrindole (10 microM), a delta-opioid receptor antagonist, completely blocked the DADLE protective effect. Administration of mu- and kappa-opioid receptor agonists (DAMGO and U50488H respectively, 5-10 microM) did not induce appreciable neuroprotection. Also, mu- or kappa-opioid receptor antagonists had no appreciable effect on the glutamate-induced injury. This study demonstrates that activation of neuronal delta-opioid receptors, but not mu- and kappa-opioid receptors, protect neocortical neurons from glutamate excitotoxicity.

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Cells, Cultured; Cytoprotection; Embryo, Mammalian; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, Leucine-2-Alanine; Excitatory Amino Acid Agonists; Female; Glutamic Acid; L-Lactate Dehydrogenase; Naltrexone; Narcotic Antagonists; Neocortex; Neurons; Pregnancy; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu

2000
An immortalized myocyte cell line, HL-1, expresses a functional delta -opioid receptor.
    Journal of molecular and cellular cardiology, 2000, Volume: 32, Issue:12

    The present study characterizes opioid receptors in an immortalized myocyte cell line, HL-1. Displacement of [(3)H]bremazocine by selective ligands for the mu (mu), delta (delta), and kappa (kappa) receptors revealed that only the delta -selective ligands could fully displace specific [(3)H]bremazocine binding, indicating the presence of only the delta -receptor in these cells. Saturation binding studies with the delta -antagonist naltrindole afforded a B(max)of 32 fmols/mg protein and a K(D)value for [(3)H]naltrindole of 0.46 n M. The binding affinities of various delta ligands for the receptor in HL-1 cell membranes obtained from competition binding assays were similar to those obtained using membranes from a neuroblastomaxglioma cell line, NG108-15. Finally, various delta -agonists were found to stimulate the binding of [(35)S]GTP gamma S, confirming coupling of the cardiac delta -receptor to G-protein. DADLE (D-Ala-D-Leu-enkephalin) was found to be the most efficacious in this assay, stimulating the binding of [(35)S]GTP gamma S to 27% above basal level. The above results indicate that the HL-1 cell line contains a functionally coupled delta -opioid receptor and therefore provides an in vitro model by which to study the direct effects of opioids on cardiac opioid receptors.

    Topics: Analgesics; Benzomorphans; Binding, Competitive; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Enkephalin, Leucine-2-Alanine; Guanosine 5'-O-(3-Thiotriphosphate); Kinetics; Ligands; Myocardium; Naltrexone; Narcotic Antagonists; Receptors, Opioid, delta; Time Factors; Tumor Cells, Cultured

2000
Constitutive activation of the delta opioid receptor by mutations in transmembrane domains III and VII.
    The Journal of biological chemistry, 1999, Jun-25, Volume: 274, Issue:26

    We have investigated whether transmembrane amino acid residues Asp128 (domain III), Tyr129 (domain III) [corrected], and Tyr308 (domain VII) in the mouse delta opioid receptor play a role in receptor activation. To do so, we have used a [35S]GTPgammaS (where GTPgammaS is guanosine 5'-3-O-(thio)triphosphate) binding assay to quantify the activation of recombinant receptors transiently expressed in COS cells and compared functional responses of D128N, D128A, Y129F, Y129A, and Y308F point-mutated receptors to that of the wild-type receptor. In the absence of ligand, [35S]GTPgammaS binding was increased for every mutant receptor under study (1.6-2.6-fold), suggesting that all mutations are able to enhance constitutive activity at the receptor. In support of this finding, the inverse agonist N,N-diallyl-Tyr-Aib-Aib-Phe-Leu (where Aib represents alpha-aminobutyric acid) efficiently reduced basal [35S]GTPgammaS binding in the mutated receptor preparations. The potent agonist BW373U86 stimulated [35S]GTPgammaS binding above basal levels with similar (D128N, Y129F, and Y129A) or markedly increased (Y308F) efficacy compared with wild-type receptor. BW373U86 potency was maintained or increased. In conclusion, our results demonstrate that the mutations under study increase functional activity of the receptor. Three-dimensional modeling suggests that Asp128 (III) and Tyr308 (VII) interact with each other and that Tyr129 (III) undergoes H bonding with His278 (VI). Thus, Asp128, Tyr129, and Tyr308 may be involved in a network of interhelical bonds, which contributes to maintain the delta receptor under an inactive conformation. We suggest that the mutations weaken helix-helix interactions and generate a receptor state that favors the active conformation and/or interacts with heterotrimeric G proteins more effectively.

    Topics: Amino Acid Substitution; Animals; Cell Membrane; COS Cells; Enkephalin, Leucine-2-Alanine; Guanosine 5'-O-(3-Thiotriphosphate); Ligands; Mice; Models, Molecular; Mutagenesis, Site-Directed; Naltrexone; Narcotic Antagonists; Protein Structure, Secondary; Receptors, Opioid, delta; Structure-Activity Relationship

1999
Mutagenesis of the mouse delta opioid receptor converts (-)-buprenorphine from a partial agonist to an antagonist.
    The Journal of pharmacology and experimental therapeutics, 1998, Volume: 284, Issue:1

    An aspartic acid at residue 95 (Asp95) in the delta receptor has previously been shown to be critical for the binding affinity of selective delta agonists. To gain a better understanding of the functional consequence of agonist action at the delta receptor, the Asp95 residue was mutated to an asparagine (D95N) and opioids were tested for binding and functional activation of the wild-type and mutant delta receptors. Selective agonists such as [D-Ser2,D-Leu5]enkephalin-Thr6 (DSLET) and [D-Ala2,D-Leu5]enkephalin (DADLE) had greatly reduced affinity for the D95N mutant receptor but still inhibited cAMP accumulation, which indicated that the mutant receptor was still functionally coupled to adenylyl cyclase. Antagonist binding was not affected by the Asp95 mutation. Similarly, the partial agonist buprenorphine bound with equally high affinity to the D95N mutant and the wild-type delta receptor, which indicated that Asp95 is not essential for the binding affinity of this opioid. Buprenorphine did not affect cAMP accumulation in HEK 293 cells expressing the D95N mutant, and it blocked the ability of DSLET and bremazocine to inhibit cAMP accumulation via the D95N mutant, which indicated that buprenorphine acts as an antagonist at the D95N mutant. These findings confirm the essential role of Asp95 in the activation of the delta receptor by agonists and reveal a molecular basis of the unique property of buprenorphine.

    Topics: Analgesics, Opioid; Animals; Buprenorphine; Cells, Cultured; Cyclic AMP; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Mice; Mutagenesis; Naltrexone; Narcotic Antagonists; Receptors, Opioid, delta

1998
Opioid receptor-mediated inhibition of omega-conotoxin GVIA-sensitive calcium channel currents in rat intracardiac neurons.
    Journal of neurophysiology, 1998, Volume: 79, Issue:2

    Modulation of depolarization-activated ionic conductances by opioid receptor agonists was investigated in isolated parasympathetic neurons from neonatal rat intracardiac ganglia by using the whole cell perforated patch clamp technique. Met-enkephalin (10 muM) altered the action potential waveform, reducing the maximum amplitude and slowing the rate of rise and repolarization but the afterhyperpolarization was not appreciably altered. Under voltage clamp, 10 muM Met-enkephalin selectively and reversibly inhibited the peak amplitude of high-voltage-activated Ca2+ channel currents elicited at 0 mV by approximately 52% and increased three- to fourfold the time to peak. Met-enkephalin had no effect on the voltage dependence of steady-state inactivation but shifted the voltage dependence of activation to more positive membrane potentials whereby stronger depolarization was required to open Ca2+ channels. Half-maximal inhibition of Ba2+ current (IBa) amplitude was obtained with 270 nM Met-enkephalin or Leu-enkephalin. The opioid receptor subtype selective agonists, DAMGO and DADLE, but not DPDPE, inhibited IBa and were antagonized by the opioid receptor antagonists, naloxone and naltrindole with IC50s of 84 nM and 1 muM, respectively. The kappa-opioid receptor agonists, bremazocine and dynorphin A, did not affect Ca2+ channel current amplitude or kinetics. Taken together, these data suggest that enkephalin-induced inhibition of Ca2+ channels in rat intracardiac neurons is mediated primarily by the mu-opioid receptor type. Addition of Met-enkephalin after exposure to 300 nM omega-conotoxin GVIA, which blocked approximately 75% of the total Ca2+ channel current, failed to cause a further decrease of the residual current. Met-enkephalin inhibited the omega-conotoxin GVIA-sensitive but not the omega-conotoxin-insensitive IBa in rat intracardiac neurons. Dialysis of the cell with a GTP-free intracellular solution or preincubation of the neurons in Pertussis toxin (PTX) abolished the attenuation of IBa by Met-enkephalin, suggesting the involvement of a PTX-sensitive Gprotein in the signal transduction pathway. The activation of mu-opioid receptors and subsequent inhibition of N-type Ca2+ channels in the soma and terminals of postganglionic intracardiac neurons is likely to inhibit the release of ACh and thereby regulate vagal transmission to the mammalian heart.

    Topics: Acetylcholine; Animals; Animals, Newborn; Anti-Arrhythmia Agents; Benzomorphans; Calcium; Calcium Channels; Dynorphins; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Enkephalin, Methionine; Enkephalins; Heart Conduction System; Ion Channel Gating; Ion Transport; Naloxone; Naltrexone; Narcotic Antagonists; Neurons; omega-Conotoxin GVIA; Parasympathetic Nervous System; Patch-Clamp Techniques; Peptides; Pertussis Toxin; Rats; Receptors, Opioid; Receptors, Opioid, kappa; Virulence Factors, Bordetella

1998
NTI4F: a non-peptide fluorescent probe selective for functional delta opioid receptors.
    Neuroscience letters, 1998, Jun-19, Volume: 249, Issue:2-3

    A non-peptide fluorescent probe, NTI4F, has been developed for the delta (delta) opioid receptor. The probe is a potent delta-antagonist in the mouse vas deferens (MVD) smooth muscle assay and it binds to the delta opioid receptor with high affinity (Ki = 1 nM) and selectivity. Confocal microscopy indicates that the probe binds to Madin-Darby canine kidney (MDCK) cells transfected with the delta opioid receptor. This binding can be blocked by the delta opioid receptor antagonist, naltrindole (NTI), but not by morphine or ethylketazocine (EK) which are mu (mu)- and kappa (kappa)-selective ligands. This fluorescent probe should prove useful in the study of the distribution of the delta opioid receptor.

    Topics: Animals; Bridged-Ring Compounds; Cell Line; Dogs; Enkephalin, Leucine-2-Alanine; Ethylketocyclazocine; Fluorescent Dyes; Imides; Microscopy, Confocal; Microscopy, Fluorescence; Morphine; Naltrexone; Receptors, Opioid, delta; Transfection

1998
Synthesis and biological activity of 3-substituted 3-desoxynaltrindole derivatives.
    Bioorganic & medicinal chemistry letters, 1998, Apr-07, Volume: 8, Issue:7

    The 3-unsubstituted and substituted analogs of naltrindole (NTI) were synthesized using palladium-catalyzed transformations, and their binding affinity to opioid receptors was determined. Although the 3-desoxy analog showed comparable delta selectivity with that of NTI, all of the novel compounds possessed low affinity for delta receptors indicating the important role of the 3-oxygen atom of NTI for interaction with delta-opioid receptors.

    Topics: Animals; Benzeneacetamides; Binding, Competitive; Brain; Cell Membrane; Drug Design; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, Leucine-2-Alanine; Enkephalins; Molecular Structure; Naltrexone; Narcotic Antagonists; Pyrrolidines; Rats; Receptors, Opioid, delta; Structure-Activity Relationship

1998
Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept.
    Journal of medicinal chemistry, 1997, Sep-26, Volume: 40, Issue:20

    This paper describes the design and synthesis of compounds belonging to a novel class of substituted pyrrolooctahydroisoquinolines which are potent and selective delta opioid agonists. Molecular modeling studies performed on known, selective delta ligands such as (+)-3 and the potent delta agonists SNC 80 led to the identification of the carboxamido moiety of the latter as a putative nonaromatic delta address. Insertion of this moiety onto the octahydroisoquinoline opioid message resulted in (+/-)-5b, a potent and selective delta ligand. The active enantiomer, (-)-5b, displayed nanomolar affinity for the delta receptor (Ki = 0.9 nM) with good mu/delta and kappa/delta binding selectivity ratios (140 and 1480, respectively). In addition, (-)-5b behaved as a full delta agonist in the mouse vas deferens bioassay having an IC50 = 25 nM and being antagonised in the presence of 30 nM naltrindole (NTI). These studies, based on the message-address concept, indicated that the nonaromatic (N,N-diethylamino)carbonyl moiety is a viable alternative to the classical benzene ring as a delta opioid address. Preliminary in vivo studies showed that (+/-)-5b produced a dose-related antinociception in the mouse abdominal constriction test after intracerebroventricular administration (ED50 = 1.6 micrograms/mouse).

    Topics: Animals; Benzamides; Brain; Computer Simulation; Dose-Response Relationship, Drug; Drug Design; Enkephalin, Leucine-2-Alanine; Indoles; Isoquinolines; Ligands; Male; Mice; Models, Molecular; Naltrexone; Narcotic Antagonists; Nociceptors; Piperazines; Pyrroles; Quinolines; Receptors, Opioid, delta; Signal Transduction; Stereoisomerism; Vas Deferens

1997
Beta-endorphin enhances Concanavalin-A-stimulated calcium mobilization by murine splenic T cells.
    Endocrinology, 1996, Volume: 137, Issue:8

    Intracellular calcium mobilization is an important early event involved in T cell activation. The endogenous opioid peptide beta-endorphin is known to modulate immune functions that depend on T cell activation, therefore its effect on intracellular calcium mobilization was investigated. The intracellular calcium concentration ([Ca2+]i) of T cell-enriched splenocytes was measured by flow cytofluorometric analysis using the calcium-sensitive dye, Fluo-3. By gating on the T cell marker, Thy-1, a 95%-pure population of T cells was identified for study. Cells preincubated with beta-endorphin showed significantly enhanced [Ca2+]i responses to the mitogen, Concanavalin A (Con A). This was detectable with concentrations of beta-endorphin as low as 10(-13) M; maximal enhancement required 10(-10) to 10(-9) M doses. The efficacy of beta-endorphin was dependent on the duration of pretreatment. beta-Endorphin amplified the Con A-induced increase in [Ca2+]i by reducing the lag time for the response to Con A and by increasing the mean [Ca2+]i of the cells. N-Ac-beta-endorphin, which shows minimal potency at neuronal opiate receptors, was unable to substitute for beta-endorphin. Naltrindole, a highly selective delta opiate receptor antagonist, inhibited the action of beta-endorphin, whereas a selective mu opiate receptor antagonist was ineffective. Although less potent than beta-endorphin, the delta opiate receptor agonist D-Ala2-D-Leu5-enkephalin also significantly enhanced [Ca2+]i responses. In summary, concentrations of beta-endorphin, within the physiological range found in the systemic circulation, modulate the increase in T cell [Ca2+]i induced by Con A. Both the efficacy of D-Ala2-D-Leu5-enkephalin alone and the antagonism of beta-endorphin by naltrindole suggest that a delta-type opiate receptor may mediate these effects.

    Topics: Animals; beta-Endorphin; Biological Transport; Calcium; Concanavalin A; Enkephalin, Leucine-2-Alanine; Female; Mice; Mice, Inbred C57BL; Naltrexone; Receptors, Opioid, delta; Spleen; T-Lymphocytes

1996
Different central opioid receptor subtype antagonists modify maltose dextrin and deprivation-induced water intake in sham feeding and sham drinking rats.
    Brain research, 1996, Nov-25, Volume: 741, Issue:1-2

    Different central opioid receptor subtypes participate in the mediation of intakes of simple (sucrose: mu, kappa 1) and complex (maltose dextrin: mu) carbohydrates as well as deprivation-induced water intake (mu) under real-feeding and real-drinking conditions. An identical pattern of mu and kappa 1 mediation of sucrose intake was observed in sham-feeding rats as well, suggesting their actions on orosensory mechanisms supporting sucose intake. The present study examined whether centrally administered general (naltrexone: 1-50 micrograms), mu (beta-funaltrexamine: 1-20 micrograms), mu 1 (naloxonazine: 50 micrograms), kappa 1 (nor-binaltorphamine: 1-20 micrograms), delta 1 ([D-Ala2, Leu5, Cys6]-enkephalin: 10-40 micrograms) or delta 2 (naltrindole isothiocyanate: 20 micrograms) opioid subtype antagonists altered either maltose dextrin (10%) intake during sham feeding or deprivation (24 h)-induced water intake during sham drinking in rats with gastric fistulas. Sham feeding significantly increased maltose dextrin intake (180%) and sham drinking significantly increased deprivation-induced water intake (256%) over a 60 min time course. Naltrexone significantly and dose-dependently reduced maltose dextrin intake (78%) in sham feeding rats, and deprivation-induced water intake (51%) in sham drinking rats. Maltose dextrin intake in sham feeding rats was significantly reduced by either kappa 1 (69%) or delta 1 (59%) opioid antagonism, was significantly increased by mu 1 antagonism (43%), and was not significantly affected by either mu or delta 2 opioid antagonism. Deprivation-induced water intake in sham drinking rats was significantly reduced by either mu (41%), mu 1 (28%), delta 1 (48%) or delta 2 (28%) opioid antagonism, but was not significantly affected by kappa 1 opioid antagonism. The difference in opioid receptor subtype mediation of maltose dextrin intake in real feeding and sham feeding conditions suggest that kappa 1 and delta 1 receptors are involved in the orosensory mechanisms supporting maltose dextrin intake, while mu receptors are involved in the ingestive and post-ingestive mechanisms supporting maltose dextrin intake. The different patterns of opioid involvement in sucrose and maltose dextrin intake in sham feeding and real feeding conditions provide further support for the hypothesis that at least two different carbohydrate taste systems exist. The difference in opioid receptor subtype mediation of deprivation-induced water intake in real drink

    Topics: Animals; Dose-Response Relationship, Drug; Drinking; Eating; Enkephalin, Leucine-2-Alanine; Injections, Intraventricular; Male; Naloxone; Naltrexone; Narcotic Antagonists; Polysaccharides; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Water Deprivation

1996
Selective actions of central mu and kappa opioid antagonists upon sucrose intake in sham-fed rats.
    Brain research, 1995, Jul-10, Volume: 685, Issue:1-2

    Intake of a palatable sucrose solution in real-fed rats is mediated in part by central mu and kappa opioid receptors. Since general opioid antagonists still inhibit sucrose intake in sham-fed rats, the present study examined whether centrally administered mu (beta-funaltrexamine: 5, 20 micrograms), mu1 (naloxonazine: 50 micrograms), kappa (nor-binaltorphamine: 1, 5, 20 micrograms), delta (naltrindole: 20 micrograms) or delta 1 (DALCE: 40 micrograms) opioid subtype antagonists altered sucrose intake in sham-fed rats in a similar manner to systemic naltrexone (0.01-1 mg/kg) and whether such effects were equivalent to altering the sucrose concentration. Sucrose (20%) intake in sham-fed rats was significantly and dose-dependently reduced by naltrexone (59%), beta-funaltrexamine (44%) and nor-binaltorphamine (62%), but not by naloxonazine, naltrindole or DALCE. The reductions in sham sucrose (20%) intake by general, mu and kappa antagonism were similar in pattern and magnitude to diluting sucrose concentration from 20% to 10% in untreated sham-fed rats. Since both real-fed and sham-fed rats share similar patterns of specificity of opioid effects, magnitudes and potencies of inhibition, it suggests that central mu and kappa antagonism acts on orosensory mechanisms supporting sucrose intake.

    Topics: Animals; Cerebral Ventricles; Eating; Enkephalin, Leucine-2-Alanine; Infusions, Parenteral; Male; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Receptors, Opioid, mu; Sucrose

1995
Analysis of central opioid receptor subtype antagonism of hypotonic and hypertonic saline intake in water-deprived rats.
    Brain research bulletin, 1995, Volume: 36, Issue:3

    Intake of either hypotonic or hypertonic saline solutions is modulated in part by the endogenous opioid system. Morphine and selective mu and delta opioid agonists increase saline intake, while general opioid antagonists reduce saline intake in rats. The present study evaluated whether intracerebroventricular administration of general (naltrexone) and selective mu (beta-funaltrexamine, 5-20 micrograms), mu, (naloxonazine, 50 micrograms), kappa (nor-binaltorphamine, 5-20 micrograms), delta (naltrindole, 20 micrograms), or delta 1 (DALCE, 40 micrograms) opioid receptor subtype antagonists altered water intake and either hypotonic (0.6%) or hypertonic (1.7%) saline intake in water-deprived (24 h) rats over a 3-h time course in a two-bottle choice test. Whereas peripheral naltrexone (0.5-2.5 mg/kg) significantly reduced water intake and hypertonic saline intake, central naltrexone (1-50 micrograms) significantly reduced water intake and hypotonic saline intake. Water intake was significantly reduced following mu and kappa receptor antagonism, but not following mu 1, delta, or delta 1 receptor antagonism. In contrast, neither hypotonic nor hypertonic saline intake was significantly altered by any selective antagonist. These data are discussed in terms of opioid receptor subtype control over saline intake relative to the animal's hydrational state and the roles of palatability and/or salt appetite.

    Topics: Animals; Enkephalin, Leucine-2-Alanine; Hypotonic Solutions; Injections, Intraventricular; Male; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Receptors, Opioid, mu; Saline Solution, Hypertonic; Water Deprivation

1995
Naltrindole sensitive delta 2 opioid receptor mediates invertebrate immunocyte activation.
    Acta biologica Hungarica, 1995, Volume: 46, Issue:2-4

    Previous studies demonstrated the presence of a delta 2 opioid receptor on human and invertebrate immunocytes. The present study demonstrates that this new binding site regulates invertebrate immunocyte activation. In the present study we note that the select delta antagonist, naltrindole, at a low concentration (10(-11) M), can significantly inhibit DAMA induced activation. Interestingly, the general opioid and opiate antagonist, naloxone, is not effective at this low concentration, further suggesting that the delta 2 opioid receptor mediates opioid immunocyte activation. This conclusion is further supported by the fact that DPDPE and DADLE, known to influence delta 1 activity did not affect immunocyte activation at low concentrations.

    Topics: Animals; Bivalvia; Enkephalin, D-Penicillamine (2,5)-; Enkephalin, Leucine-2-Alanine; Enkephalin, Methionine; Enkephalins; Humans; Immune System; Naloxone; Naltrexone; Narcotic Antagonists; Receptors, Opioid, delta

1995
Evidence for functional delta-opiate receptors in the rat intestine.
    The Journal of pharmacy and pharmacology, 1994, Volume: 46, Issue:10

    The selective delta-opiate agonists D-Ser2, Leu5, Thr6-enkephalin (DSLET), D-Ala2, D-Leu5-enkephalin and D-Pen2, D-Pen5-enkephalin caused inhibition of the cholinergic contraction produced by transmural stimulation of the rat isolated jejunum. Dynorphin A, which is an agonist at both kappa- and delta-opioid receptors also inhibited the cholinergic contraction, as did leu- and met-enkephalin. The selective mu-receptor agonist D-Ala2-NMe-Phe4, Gly-ol5-enkephalin was the least potent of all peptides tested. In general, the order of potency of the peptides was similar to that reported for the delta-receptor-rich mouse vas deferens with potency values similar to those recorded previously for the hamster vas deferens. The selective delta-opioid antagonist naltrindole caused parallel shifts to the concentration-effect curve to DSLET giving a pA2 value of 10.15. The results indicate that the previously identified delta-binding sites in the rat jejunum may correspond to functional delta-opiate receptors involved in attenuating acetylcholine release.

    Topics: Acetylcholine; Animals; Cricetinae; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Female; In Vitro Techniques; Jejunum; Male; Mice; Muscle Contraction; Muscle, Smooth; Naltrexone; Rats; Rats, Wistar; Receptors, Opioid, delta

1994
Differential modulation of angiotensin II and hypertonic saline-induced drinking by opioid receptor subtype antagonists in rats.
    Brain research, 1994, 01-28, Volume: 635, Issue:1-2

    Opioid modulation of ingestion includes general opioid antagonism of different forms of water intake, mu 2 receptor modulation of deprivation-induced water intake and delta 2 receptor modulation of saccharin intake. Water intake is stimulated by both central administration of angiotensin II (ANG II) and peripheral administration of a hypertonic saline solution; both responses are reduced by general opioid antagonists. The present study examined whether specific opioid receptor subtype antagonists would selectively alter each form of water intake in rats. Whereas systemic naltrexone (0.1-2.5 mg/kg, s.c.) reduced water intake induced by either peripheral ANGII (500 micrograms/kg, s.c.) or hypertonic saline (3 ml/kg, 10%), intracerebroventricular (i.c.v.) naltrexone (1-50 micrograms) only inhibited central ANGII (20 ng)-induced hyperdipsia. Both forms of drinking were significantly and dose-dependently inhibited by the selective kappa antagonist, nor-binaltorphamine (Nor-BNI, 1-20 micrograms). Whereas both forms of drinking were transiently reduced by the mu-selective antagonist, beta-funaltrexamine (beta-FNA, 1-20 micrograms), the mu 1 antagonist, naloxonazine (40 micrograms) stimulated drinking following hypertonic saline. The delta 1 antagonist, [D-Ala2, Leu5, Cys6]-enkephalin (DALCE, 1-40 micrograms) significantly reduced drinking following ANGII, but not following hypertonic saline; the delta antagonist, naltrindole failed to exert significant effects. These data indicate that whereas kappa opioid binding sites modulate hyperdipsia following hypertonic saline, mu 2, delta 1, and kappa opioid binding sites modulate hyperdipsia following ANGII. The mu 1 opioid binding site may normally act to inhibit drinking following saline.

    Topics: Angiotensin II; Animals; Drinking; Enkephalin, Leucine-2-Alanine; Male; Naltrexone; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, mu; Saline Solution, Hypertonic

1994
Delta-opioid receptor antagonists attenuate motor activity induced by amphetamine but not cocaine.
    European journal of pharmacology, 1993, Nov-09, Volume: 249, Issue:2

    Naloxone and naltrindole attenuate the locomotor response to amphetamine, implicating delta-opioid receptors in the opioid-antagonist/amphetamine interaction. To determine the role of delta-opioid receptor subtypes in this phenomenon, rats were pretreated with the following selective antagonists administered intracisternally: naltrindole, [D-Ala2,Leu5,Cys6]enkephalin (DALCE, delta 1 receptor selective), naltrindole-5'-isothiocyanate (delta 2 receptor selective). Cumulative dose-response curves to amphetamine were constructed (saline, 0.1, 0.4, 1.6 and 6.4 mg/kg s.c.), with injections every 30 min. Naltrindole was also tested against cumulative doses of cocaine (saline, 3.0, 10, 30 and 56 mg/kg i.p.). Gross and fine motor activity were recorded for 20 min, commencing 10 min postinjection. Amphetamine and cocaine dose dependently increased both gross and fine movements. Naltrindole (10 micrograms) attenuated the gross but not fine activity response to amphetamine, but 10 or 30 micrograms failed to influence the response to cocaine. Naltrindole-5'-isothiocyanate (30 micrograms) attenuated slightly but significantly the gross activity response to amphetamine, whereas DALCE (30 micrograms) was without effect. However, a combination of 10 micrograms each of DALCE and naltrindole-5'-isothiocyanate markedly attenuated the amphetamine-induced increases in gross movements without altering fine activity. These data provide further evidence for the involvement of delta-opioid receptors in the modulation of behavioral effects of amphetamine; both delta 1- and delta 2-opioid receptors appear to play a role. The differential effects of opioid antagonists on locomotor activity stimulated by amphetamine and cocaine suggests differences in the mechanism of action of these drugs not previously appreciated.

    Topics: Amphetamine; Animals; Cocaine; Dose-Response Relationship, Drug; Enkephalin, Leucine-2-Alanine; Male; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta

1993
Involvement of mu1 and mu2 opioid receptor subtypes in tail-pinch feeding in rats.
    Physiology & behavior, 1993, Volume: 53, Issue:3

    Tail-pinch feeding (TPF) in rats is decreased following general (naltrexone, NTX) and mu (Cys2-Tyr3-Orn5-Pen7-amide, CTOP) opioid antagonists, but not following kappa (nor-binaltorphamine. Nor-BNI) or delta (naltrindole, NTI) opioid antagonists. Because multiple mu (mu1 and mu2) and delta (delta 1 and delta 2) opioid receptor subtypes have been characterized, the present study evaluated whether TPF was differentially altered following ICV administration of general (NTX), mu (beta-funaltrexamine, B-FNA), mu1 (naloxonazine, NAZ), kappa (Nor-BNI), delta 1 ([D-Ala2, Leu5, Cys6]-enkephalin, DALCE) and delta 2 (NTI) opioid antagonists. Like the reversible mu antagonist CTOP, the irreversible mu antagonist B-FNA significantly and dose-dependently (1-20 micrograms) reduced TPF by up to 28%. In contrast, whereas NAZ (50 micrograms) reduced TPF by 32%, this effect was highly variable and failed to achieve significance. Neither NTX (5-10 mg/kg, SC), Nor-BNI (20 micrograms), DALCE (40 micrograms) nor NTI (20 micrograms) significantly altered TPF, suggesting that kappa, delta 1 and delta 2 opioid receptor subtypes were not involved. Because no antagonist altered the duration of food contact during tail pinch, it appears that the opioid effect modulates ingestive rather than activational mechanisms. The reliable inhibition of TPF by B-FNA (mu1 and mu2), together with the variable effect of naloxonazine (mu1), appears to implicate both mu binding sites in this response.

    Topics: Animals; Arousal; Enkephalin, Leucine-2-Alanine; Feeding Behavior; Indoles; Male; Morphinans; Naloxone; Naltrexone; Narcotic Antagonists; Nociceptors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu

1993
Dose-dependent antagonism of spinal opioid receptor agonists by naloxone and naltrindole: additional evidence for delta-opioid receptor subtypes in the rat.
    European journal of pharmacology, 1993, May-12, Volume: 236, Issue:1

    Intrathecally administered mu-opioid (morphine; DAMGO ([D-Ala2,N-MePhe4,Gly5-ol]enkephalin)) and delta-opioid (DPDPE ([D-Pen2,D-Pen5] enkephalin); DADLE ([D-Ala2,D-Leu5]enkephalin)) receptor preferring agonists were systematically challenged with the competitive opiate antagonists naloxone or naltrindole in the rat. Naloxone produced a dose-dependent reduction in agonist effect with the intrathecal IC50 being similar for all agonists (2.1-5.4 micrograms). In contrast, the naltrindole antagonist profile was (IC50 in micrograms) DPDPE (4.0); morphine (23.5); DADLE (> 30) and DAMGO (> 30). Three points are emphasized: (1) antagonism of DPDPE and not DAMGO by naltrindole suggests two distinct opioid sites; (2) a similar potency for naloxone against these agonists suggests that the agonists may act upon spinal sites for which naloxone has comparable affinity or that they may act upon separate sites which are functionally coupled and that the action of naloxone on one or the other site is responsible for the antagonism; and (3) given the modest cross-tolerance between DADLE and mu agonists, the failure of naltrindole to antagonize DADLE suggests that in the rat this peptide acts through a delta site different from that acted upon by DPDPE.

    Topics: Analgesics; Animals; Binding, Competitive; Dose-Response Relationship, Drug; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Enkephalin, Leucine-2-Alanine; Enkephalins; In Vitro Techniques; Injections, Spinal; Male; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, mu; Spinal Cord

1993
Central opioid receptor subtype antagonists differentially reduce intake of saccharin and maltose dextrin solutions in rats.
    Brain research, 1993, Aug-06, Volume: 618, Issue:2

    Opioid modulation of ingestion includes general opioid antagonism of deprivation-induced water intake and intake of sucrose and saccharin solutions. Previous studies using selective subtype antagonists indicated that opioid effects upon deprivation-induced water intake occurred through the mu2 receptor and that opioid effects upon sucrose intake occurred through kappa and mu2 receptors. The present study compared the effects of intracerebroventricular administration of opioid receptor subtype antagonists upon intakes of a saccharin solution and a maltose dextrin (MD) solution to determine which receptor subtypes were involved in modulation of ingestion of different preferred tastants. Significant reductions in saccharin intake (1 h) occurred following naltrexone (20-50 micrograms: 66%) and naltrindole (delta, 20 micrograms: 75%), whereas [D-Ala2, Leu5, Cys6]-enkephalin (DALCE, delta 1, 40 micrograms: 45%) had transient (5 min) effects. Neither beta-funaltrexamine (B-FNA, mu), naloxonazine (mu1), nor nor-binaltorphamine (Nor-BNI, kappa) significantly altered saccharin intake. Significant reductions in MD intake (1 h) occurred following naltrexone (5-50 micrograms: 69%) and B-FNA (1-20 micrograms: 38%). MD intake was not reduced by naltrindole, DALCE, naloxonazine and Nor-BNI. Peak antagonist effects were delayed (20-25 min) to reflect interference with the maintenance, rather than the initiation of saccharin or MD intake. Comparisons of opioid antagonist effects across intake situations revealed that naltrexone had consistently low ID40 values for saccharin (29 nmol), MD (25 nmol), sucrose (6 nmol) and deprivation (38 nmol) intake. Despite its significant effects relative to naloxonazine, B-FNA had significantly higher ID40 values for saccharin (800 nmol), MD (763 nmol) and sucrose (508 nmol) relative to deprivation (99 nmol) intake, suggesting that mu2 receptors may be mediating maintenance of intake rather than taste effects. Nor-BNI had low ID40 values for intake of sucrose (4 nmol), but not for saccharin (168 nmol), MD (153 nmol) and deprivation (176 nmol), suggesting that kappa receptors may mediate ingestion of sweet-tasting stimuli. That delta (naltrindole: ID40 = 60 nmol), but not delta 1 (DALCE: ID40 = 288 nmol) antagonists consistently reduce saccharin intake suggests a role for the delta 2 receptor subtype in the modulation of hedonic orosensory signals.

    Topics: Animals; Drinking Behavior; Enkephalin, Leucine-2-Alanine; Injections, Intraventricular; Male; Naloxone; Naltrexone; Narcotic Antagonists; Polysaccharides; Rats; Rats, Sprague-Dawley; Saccharin

1993
Kinetic parameters of antagonism by the delta opioid receptor selective peptide antagonist Boc-Tyr-Pro-Gly-Phe-Leu-Thr against selective and non-selective agonists in the mouse vas deferens.
    Neuropeptides, 1993, Volume: 25, Issue:2

    The kinetic parameters of antagonism by the delta opioid receptor selective antagonist N-t-Boc-Tyr-Pro-Gly-Phe-Leu-Thr, obtained by using moderately selective or selective agonists, were compared in the mouse vas deferens bioassay. The apparent affinity for the preferred receptor type was 6.8 times higher when selective agonist was used, resulting in a Ke of 81.4 nM (66.3-99.9, n = 6) against [D-Ala2, D-Leu5]-enkephalin, with a 3700-fold delta over mu or kappa selectivity ratio.

    Topics: Analgesics; Animals; Anticonvulsants; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, Leucine-2-Alanine; Enkephalin, Methionine; Enkephalins; In Vitro Techniques; Kinetics; Male; Mice; Mice, Inbred Strains; Morphine Derivatives; Naltrexone; Oligopeptides; Pyrroles; Receptors, Opioid, delta; Thiophenes; Vas Deferens

1993
(D-Ala, D-Leu) enkephalin reduces the binding of GTP in hippocampal membranes.
    Life sciences, 1993, Volume: 52, Issue:11

    The effect of (D-Ala, D-Leu) enkephalin (DADLE) on the binding of GTP in hippocampal preparations was studied. It was observed that treatment of hippocampal slices with 10(-5) -5 x 10(-5) M DADLE followed by the preparation of membrane fractions reduced the binding of 35S-GTP-gamma-S. There was no change in the affinity of the binding. This decrease of 35S-GTP-gamma-S binding was reversed when 5 x 10(-5) M naltrindole was included. The effect was not observed when the membrane fractions were incubated with DADLE. Photoaffinity labeling with the use of 32P P3-(4-azidoanilido)-P1 5'-GTP followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography revealed the incorporation of radioactivity into molecular mass of the 43 kDa and 33-34 kDa proteins. 32P Photolabeling of both the 43 kDa and 33-34 kDa bands decreased following treatment of hippocampal slices with 10(-4) M DADLE. These results suggested that DADLE reduces the GDP-GTP exchange in hippocampal membranes.

    Topics: Affinity Labels; Animals; Autoradiography; Azides; Electrophoresis, Polyacrylamide Gel; Enkephalin, Leucine-2-Alanine; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Guanosine Triphosphate; Hippocampus; In Vitro Techniques; Indoles; Male; Membranes; Morphinans; Naltrexone; Rats; Rats, Sprague-Dawley

1993
Isobolographic and dose-response analyses of the interaction between intrathecal mu and delta agonists: effects of naltrindole and its benzofuran analog (NTB).
    The Journal of pharmacology and experimental therapeutics, 1992, Volume: 263, Issue:1

    Intrathecal administration of DPDPE, PL017, DAMGO, morphine and DADLE produced a dose-dependent increase in hot plate response latency, with the order of potency (ED50 nmol) being: DAMGO (0.17) > DADLE (0.70) > or = PL017 (1.2) > morphine (15) > DPDPE (130). Characteristics of the spinal mu and delta interaction were determined independently by two methods. 1) In the presence of a fixed dose of DPDPE (150 nmol), there was a left shift in the dose-response curve of the mu agonist, with the magnitude of the shifts being greater than those anticipated from a simple additive interaction: PL017 (31-fold) > or = DAMGO (20-fold) > morphine (6.5-fold) > 4-fold (theoretical additive shift). 2) With an isobolographic analysis, a statistically significant nonlinearity was observed, suggesting a multiplicative interaction upon coadministration of the delta-selective ligand DPDPE together with all the tested mu-selective agonists. Examining antagonist activity, mu agonists were antagonized in a dose-dependent fashion by naloxone and naltrindole-benzofuran analog, whereas DPDPE was reversed by all three antagonists used, naltrindole, naltrindole-benzofuran analog and naloxone. The synergic effect produced by the coadministration of PL017 and DPDPE, was reversed in a dose-dependent fashion by all three antagonists, suggesting that the interaction requires the concurrent agonist occupancy of mu and delta receptors.

    Topics: Analgesia; Animals; Dose-Response Relationship, Drug; Drug Interactions; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, Leucine-2-Alanine; Enkephalins; Indoles; Injections, Spinal; Male; Morphinans; Morphine; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, mu

1992
A lack of potency for the delta-opioid antagonist naltrindole after microinjection into the rostral ventrolateral medulla of rabbits.
    Clinical and experimental pharmacology & physiology, 1990, Volume: 17, Issue:7

    1. Naltrindole is a novel delta-opioid antagonist which is highly potent in vitro. We examined the effects on arterial pressure of naltrindole (0.3-300 pmol) after microinjection into the pressor area of the rostral ventrolateral medulla of chloralose-anaesthetized rabbits. 2. Naltrindole itself had no significant effects on arterial pressure, and only slightly attenuated the hypotensive effect of an exogenous agonist ( [D-Ala2, D-Leu5]-enkephalin). This is in contrast to previous demonstration of a marked pressor effect following another delta-antagonist, ICI 174,864. 3. Thus, naltrindole, tested in vivo against endogenous opioid effects, does not appear to be as potent as it is in vitro, and in this case was virtually ineffective.

    Topics: Animals; Blood Pressure; Dose-Response Relationship, Drug; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Indoles; Male; Medulla Oblongata; Microinjections; Morphinans; Naltrexone; Narcotic Antagonists; Rabbits; Receptors, Opioid; Receptors, Opioid, delta

1990